These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3735874)

  • 1. [Hormone-resistant and hormonally treated recurrent prostatic cancer--prognosis of therapeutic change based on sequential biopsy].
    Yoshida K; Hasegawa J; Yui Y; Nishimura T; Akimoto M
    Nihon Hinyokika Gakkai Zasshi; 1986 Mar; 77(3):489-94. PubMed ID: 3735874
    [No Abstract]   [Full Text] [Related]  

  • 2. Scientific background of hormonal treatment of prostate cancer.
    Klijn JG
    Prog Clin Biol Res; 1990; 357():7-22. PubMed ID: 2217480
    [No Abstract]   [Full Text] [Related]  

  • 3. Overview of hormonal therapy for prostate cancer.
    Carter HB; Isaacs JT
    Prog Clin Biol Res; 1990; 350():129-40. PubMed ID: 2201039
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.
    Eisenberger MA; Crawford ED; Wolf M; Blumenstein B; McLeod DG; Benson R; Dorr FA; Benson M; Spaulding JT
    Semin Oncol; 1994 Oct; 21(5):613-9. PubMed ID: 7939752
    [No Abstract]   [Full Text] [Related]  

  • 5. What is new in endocrine therapy of prostatic cancer?
    Schröder FH
    Prog Clin Biol Res; 1990; 357():45-52. PubMed ID: 2217477
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Hashimoto J; Takayanagi A; Fukuta F; Tsukamoto T
    Jpn J Clin Oncol; 2011 Mar; 41(3):405-10. PubMed ID: 20947624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there still place for estrogens in the treatment of advanced prostatic carcinoma?
    Steg A
    Prog Clin Biol Res; 1987; 243B():429-34. PubMed ID: 3309995
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer and Leukemia Group B trials for advanced prostate cancer.
    Small EJ; Dawson NA; Kantoff PW; Vogelzang NJ
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):28-31. PubMed ID: 8996582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality of life of patients with prostatic cancer under hormonal therapy].
    Aliaev IuG; Aslamazov EG; Demidko IuL
    Urologiia; 2010; (1):46, 48-51. PubMed ID: 20891045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of prostate volume by ultrasound in hormonally treated prostate cancer.
    Brandt B; Menu G; el Khansa A; Lardennois B
    Prog Clin Biol Res; 1987; 243B():13-9. PubMed ID: 3309979
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of surgery in the treatment of hormone resistant prostatic cancer.
    Benson MC
    Prog Clin Biol Res; 1987; 243B():457-60. PubMed ID: 2443924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metastases in hormone refractory prostate cancer: a changing natural history?
    Roberts-Thomson R; Rosenthal MA; Gonzales M; Drummond K
    Intern Med J; 2009 Mar; 39(3):205-6. PubMed ID: 19383072
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormonal therapy of prostate cancer: current concepts and future prospects.
    Smith JA
    Clin Ther; 1988; 10(3):281-6. PubMed ID: 3078908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormone therapy in prostate cancer: clinical results].
    Morote-Robles J
    Rev Esp Fisiol; 1990 Mar; 46(1):59-62. PubMed ID: 1697693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Canadian trials in hormonally resistant prostate cancer.
    Moore MJ; Tannock IF
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):15-9. PubMed ID: 8996579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    Walsh PC
    J Urol; 2005 Jun; 173(6):1966. PubMed ID: 15879792
    [No Abstract]   [Full Text] [Related]  

  • 17. Investigating the response of prostatic cancer to endocrine therapy.
    Shimazaki J; Isaka S; Akimoto S; Sumiya H; Masai M; Higa T
    Prog Clin Biol Res; 1990; 357():59-67. PubMed ID: 1699239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine therapy of breast and prostate cancer.
    Manni A
    Endocrinol Metab Clin North Am; 1989 Jun; 18(2):569-92. PubMed ID: 2663486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of thalidomide in androgen-independent prostate cancer.
    Cox MC; Dahut WL; Figg WD
    Urol Oncol; 2006; 24(3):246-9. PubMed ID: 16678058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of primary stage D prostatic cancer.
    Benson MC
    Prog Clin Biol Res; 1987; 243B():411-28. PubMed ID: 3309994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.